Trial · NCT01986348
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| 6-Month Progression-Free Survival (PFS) Rate | Arm B: Selinexor 50 mg/m^2 | 9.72 | 95% Confidence Interval 2.67 to 35.39 | percentage of participants | |
| 6-Month Progression-Free Survival (PFS) Rate | Arm C: Selinexor 60 mg | 7.69 | 95% Confidence Interval 1.17 to 50.57 | percentage of participants | |
| 6-Month Progression-Free Survival (PFS) Rate | Arm D: Selinexor 80 mg | 17.24 | 95% Confidence Interval 7.77 to 38.27 | percentage of participants | |
| Overall Response Rate (ORR) | Arm B: Selinexor 50 mg/m^2 | 8.3 | 95% Confidence Interval 1.0 to 27.0 | percentage of participants | |
| Overall Response Rate (ORR) | Arm C: Selinexor 60 mg | 7.7 | 95% Confidence Interval 0.2 to 36.0 | percentage of participants | |
| Overall Response Rate (ORR) | Arm D: Selinexor 80 mg | 10.0 | 95% Confidence Interval 2.1 to 26.5 | percentage of participants | |
| Overall Survival (OS) | Arm B: Selinexor 50 mg/m^2 | 10.51 | 95% Confidence Interval 4.93 to 16.95 | months | |
| Overall Survival (OS) | Arm C: Selinexor 60 mg | 8.48 | 95% Confidence Interval 7.29 to NA | months | |
| Overall Survival (OS) | Arm D: Selinexor 80 mg | 10.15 | 95% Confidence Interval 7.03 to 15.38 | months | |
| Progression-free Survival (PFS) | Arm B: Selinexor 50 mg/m^2 | 1.64 | 95% Confidence Interval 1.18 to 3.15 | months | |
| Progression-free Survival (PFS) | Arm C: Selinexor 60 mg | 1.87 | 95% Confidence Interval 1.84 to 14.88 | months | |
| Progression-free Survival (PFS) | Arm D: Selinexor 80 mg | 1.87 | 95% Confidence Interval 1.81 to 3.02 | months | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Arm A: Selinexor 60 mg and Surgery | Participants with TEAEs | 8 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Arm B: Selinexor 50 mg/m^2 | Participants with TEAEs | 24 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Arm C: Selinexor 60 mg | Participants with TEAEs | 14 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Arm D: Selinexor 80 mg | Participants with TEAEs | 30 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Arm A: Selinexor 60 mg and Surgery | Participants with TESAEs | 5 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Arm B: Selinexor 50 mg/m^2 | Participants with TESAEs | 7 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Arm C: Selinexor 60 mg | Participants with TESAEs | 7 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Arm D: Selinexor 80 mg | Participants with TESAEs | 7 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01986348/results